Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Phase 3 Clinical Trial Investigating Optimal Duration of Oxaliplatin Administration in Postoperative XELOX (Oxaliplatin + Capecitabine) Adjuvant Chemotherapy for the Patients With Stage II/III Gastric Cancer

NCT04787354 is registered in ClinicalTrials.gov with Hallym University Medical Center as lead sponsor.

NCT NCT04787354
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04787354 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Phase 3 Clinical Trial Investigating Optimal Duration of Oxaliplatin Administration in Postoperative XELOX (Oxaliplatin + Capecitabine) Adjuvant Chemotherapy for the Patients With Stage II/III Gastric Cancer
Lead sponsor
Hallym University Medical Center
Phase
Phase 3
Overall status
Recruiting
Start date
November 1, 2021
Completion date
December 31, 2027
Enrollment
976 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

gastric cancer